Document:

Exhibit 10.4

 

Power of Attorney

 

We, Hexin Fengze Asset Management (Beijing) Co., Ltd., a corporation organized and existing under the laws of the PRC, with address at Room 512, Floor 5, Jia No. 92 Jianguo Road, Chaoyang District, Beijing, and a holder of 100% of the entire registered capital in Beijing Hexin Jiuding Technology Co., Ltd. (“Hexin Jiuding”) as of the date when the Power of Attorney is executed, hereby irrevocably authorize Beijing Hexin Yongheng Technology Development Co., Ltd. (“WFOE”) to exercise the following rights relating to all equity interests held by us now and in the future in Hexin Jiuding (“Our Shareholding”) during the term of this Power of Attorney:

 

WFOE is hereby authorized to act on behalf of us as our exclusive agent and attorney with respect to all matters concerning Our Shareholding, including without limitation to: 1) attending shareholders’ meetings of Hexin Jiuding; 2) exercising all the shareholder’s rights and shareholder’s voting rights we are entitled to under the laws of China and Hexin Jiuding’s Articles of Association, including but not limited to the sale or transfer or pledge or disposition of Our Shareholding in part or in whole; and 3) designate and appoint on behalf of us the legal representative, the directors, supervisors, the chief executive officer and other senior management members of Hexin Jiuding.

 

Without limiting the generality of the powers granted hereunder, WFOE shall have the power and authority to, on behalf of us, execute all the documents we shall sign as stipulated in the Exclusive Option Agreement entered into by and among us, WFOE and Hexin Jiuding on January 1, 2021 and the Equity Pledge Agreement entered into by and among us, WFOE and Hexin Jiuding on January 1, 2021 (including any modification, amendment and restatement thereto, collectively the “Transaction Documents”), and perform the terms of the Transaction Documents.

 

All the actions associated with Our Shareholding conducted by WFOE shall be deemed as our own actions, and all the documents related to Our Shareholding executed by WFOE shall be deemed to be executed by us.  We hereby acknowledge and ratify those actions and/or documents by WFOE.

 

WFOE is entitled to re-authorize or assign its rights related to the aforesaid matters to any other person or entity at its own discretion and without giving prior notice to us or obtaining our consent. If required by PRC laws, WFOE shall designate a PRC citizen to exercise the aforementioned rights.

 

During the period that we are the shareholder of Hexin Jiuding, this Power of Attorney shall be irrevocable and continuously effective and valid from the date of execution of this Power of Attorney.

 

1

 

During the term of this Power of Attorney, we hereby waive all the rights associated with Our Shareholding, which have been authorized to WFOE through this Power of Attorney, and shall not exercise such rights by us.

 

This Power of Attorney is written in Chinese and English.  In case of any discrepancy between the Chinese version and the English version, the Chinese version shall prevail.

 

This Power of Attorney is signed on January  1, 2021.

 

2

 

	
 
    	
Hexin Fengze Asset Management   (Beijing) Co., Ltd.
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Xiaobo An
    
	
 
    	
Name:
    	
Xiaobo An
    
	
 
    	
Title:
    	
Legal Representative
    

 

	
Accepted by
    	
 
    
	
 
    	
 
    
	
Beijing Hexin Yongheng Technology Development   Co., Ltd.
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ Xiaobo An
    	
 
    
	
Name:
    	
Xiaobo An
    	
 
    
	
Title:
    	
Legal Representative
    	
 
    
	
 
    	
 
    	
 
    
	
Acknowledged by:
    	
 
    
	
Beijing Hexin Jiuding   Technology Co., Ltd.
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ Xiaobo An
    	
 
    
	
Name:
    	
Xiaobo An
    	
 
    
	
Title:
    	
Legal Representative
    	
 
    
				

 

3ex_222515.htm

 

Exhibit 10.1

 

Amendment no. 5 to term loan agreement

 

THIS AMENDMENT NO. 5 TO TERM LOAN AGREEMENT dated as of January 22, 2021 (this “Agreement”), is made among AVINGER, INC., a Delaware corporation (“Borrower”), the Subsidiary Guarantors from time to time party thereto (together with Borrower, the Obligors”), the Lenders listed on the signature pages hereto under the heading “LENDERS” (each a “Lender” and, collectively, “Lenders”), with respect to the Loan Agreement referred to below.

 

RECITALS

 

WHEREAS, Borrower, the Subsidiary Guarantors from time to time party thereto, and the Lenders are parties to the Term Loan Agreement, dated as of September 22, 2015, as amended by Amendment 1 to Term Loan Agreement, dated as of October 28, 2016, as further amended by Amendment No. 2 to Term Loan Agreement, dated as of February 14, 2018, as further amended by Amendment No. 3 to Term Loan Agreement, dated as of March 2, 2020, as further amended by Amendment No. 4 and Waiver to Term Loan Agreement, dated as of May 12, 2020 and as modified by the Waiver and Consent, dated as of December 14, 2017, the Waiver and Consent, dated as of January 24, 2018, the Waiver and Consent, dated as of April 5, 2019, the Waiver and Consent, dated as of July 24, 2019, the Waiver and Consent, dated as of March 2, 2020, the Consent, dated as of April 20, 2020, and the Waiver and Consent, dated as of August 3, 2018 (as amended, restated, modified or otherwise supplemented from time to time, the “Loan Agreement”).

 

WHEREAS, Borrower has requested that the Lenders (which Lenders constitute all of the Lenders party to the Loan Agreement as required by Section 12.04 of the Loan Agreement), and the Lenders have agreed to, amend Loan Agreement on the terms and subject to the conditions set forth herein.

 

AGREEMENT

 

NOW THEREFORE, accordingly, the parties hereto agree as follows.

 

SECTION 1.     Definitions; Interpretation.

 

(a)     Terms Defined in Loan Agreement. All capitalized terms used in this Agreement (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement.

 

(b)     Interpretation. The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Agreement and are incorporated herein by this reference.

 

SECTION 2.     Amendments to Loan Agreement. Subject to Section 3, the Loan Agreement is hereby amended as follows:

 

(a)     The following definition is hereby added to Section 1.01 of the Loan Agreement to appear in appropriate alphabetical order:

 

“Fifth Amendment Effective Date” means January 22, 2021.

 

 

 

 

(b)     The following definitions in Section 1.01 of the Loan Agreement shall be amended and restated in their entirety as follows:

 

““Interest-Only Period” means the period from and including the first Borrowing Date and through and including the thirty-fourth (34th) Payment Date after the first Borrowing Date, which is December 31, 2023.”

 

““Maturity Date” means the earlier to occur of (i) the Stated Maturity Date, and (ii) the date on which the Loans are accelerated pursuant to Section 11.02.”

 

““PIK Period” means the period beginning on the first Borrowing Date through and including the earlier to occur of (i) thirty-fourth (34th) Payment Date after the first Borrowing Date, which is December 31, 2023 and (ii) the date on which any Default shall have occurred (provided that if such Default shall have been cured or waived, the PIK Period shall resume until the earlier to occur of the next Default and December 31, 2023).”

 

““Stated Maturity Date” means the forty-second (42nd) Payment Date following the Closing Date, which is December 31, 2025.”

 

(c)     Section 3.02(d) of the Loan Agreement shall be amended and restated in the entirety to read as follows:

 

“(d)     Paid In-Kind Interest. Notwithstanding Section 3.01(a), at any time during the PIK Period, Borrower may elect to pay the interest on the outstanding principal amount of the Loans payable pursuant to Section 3.01 as follows: (i) only 8.50% of the 12.50% per annum interest in cash and (ii) 4.00% of the 12.50% per annum interest as compounded interest, added to the aggregate principal amount of the Loans (the amount of any such compounded interest being a “PIK Loan”). At the request of any Lender, each PIK Loan of such Lender may be evidenced by a Note in the form of Exhibit C-2; provided that, for the Payment Dates commencing with the eleventh (11th) Payment Date following the Closing Date and continuing through and including December 31, 2023, Borrower may elect to pay such interest on the outstanding principal amount of the Loans entirely in the form of PIK Loans provided further that no Default shall have occurred and be continuing as of each such Payment Date. The principal amount of each PIK Loan shall accrue interest in accordance with the provisions of this Agreement applicable to the Loans.”

 

(d)     Section 7.04(b) of the Loan Agreement shall be amended and restated in its entirety as follows:

 

“(b) No Material Adverse Change. Since December 31, 2020, there has been no Material Adverse Change, provided that any adverse change in or effect upon the revenue of the Borrower and its Subsidiaries taken as a whole relating to the impacts of the COVID-19 pandemic which were disclosed to the Lenders as of the Fifth Amendment Effective Date or which were otherwise publicly available on or prior to the Fifth Amendment Effective Date shall be disregarded for purposes of this clause (b).”

 

2

 

 

(e)     Section 10.02 of the Loan Agreement shall be amended and restated to amend and restate clause (f) through (h) in their entirety and to add new clauses (i) through (k) as follows:

 

“(f) [Reserved];

 

(g)     during the twelve month period beginning on January 1, 2021, of at least $8,000,000;

 

(h)     during the twelve month period beginning on January 1, 2022, of at least $10,000,000

 

(i)      during the twelve month period beginning on January 1, 2023, of at least $12,000,000;

 

(j)      during the twelve month period beginning on January 1, 2024, of at least $14,500,000; and

 

(k)     during the twelve month period beginning on January 1, 2025, of at least $17,000,000.”

 

(f)     Section 11.01(o) of the Loan Agreement shall be amended and restated in its entirety as follows:

 

“(o) a Material Adverse Change shall have occurred; provided that any adverse change in or effect upon the revenue of the Borrower and its Subsidiaries taken as a whole relating to the impacts of the COVID-19 pandemic which were disclosed to the Lenders as of the Fifth Amendment Effective Date or which were otherwise publicly available on or prior to the Fifth Amendment Effective Date shall be disregarded for purposes of this clause (o).”

 

(g)     Annex B of Exhibit E of the Loan Agreement is hereby replaced in its entirety by Annex B to Compliance Certificate attached hereto.     

 

SECTION 3.     Conditions to Effectiveness. The effectiveness of Section 2 shall be subject to the satisfaction of each of the following conditions precedent:

 

(a)     Borrower and all of the Lenders shall have duly executed and delivered this Agreement pursuant to Section 12.04 of the Loan Agreement; provided, however, that this Agreement shall have no binding force or effect unless all conditions set forth in this Section 3 have been satisfied.

 

(b)     The Borrower shall have paid or reimbursed Lenders for Lenders’ reasonable out of pocket costs and expense incurred in connection with this Agreement, including Lenders’ reasonable and documented out of pocket legal fees and costs, pursuant to Section 12.03(a)(i)(z) of the Loan Agreement.

 

3

 

 

(c)     No Default or Event of Default shall have occurred and be continuing.

 

SECTION 4.     Representations and Warranties. Each Obligor hereby represents and warrants to each Lender as follows:

 

(i)     Such Obligor has full power, authority and legal right to make and perform this Agreement. This Agreement is within such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Agreement has been duly executed and delivered by such Obligor and constitutes a legal, valid and binding obligation of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Agreement (x) does not require any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect and the filing of a copy of this Agreement with the SEC following its effectiveness, (y) will not violate any applicable law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right thereunder to require any payment to be made by any such Person.

 

(ii)      No Default has occurred or is continuing or will result after giving effect to this Agreement.

 

(iii)     There has been no Material Adverse Effect since the date of the Loan Agreement.

 

(iv)     The representations and warranties made by or with respect to such Obligor in Section 7 of the Loan Agreement are (A) in the case of representations qualified by “materiality,” “Material Adverse Effect” or similar language, true and correct in all respects and (B) in the case of all other representations and warranties, true and correct in all material respects (except that the representation regarding representations and warranties that refer to a specific earlier date are true and correct on the basis set forth above as of such earlier date), in each case taking into account any changes made to schedules updated in accordance with Section 7.21 of the Loan Agreement or attached hereto.

 

SECTION 5.     Reaffirmation. Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Agreement, except as expressly provided herein. By executing this Agreement, each Obligor acknowledges that it has read, consulted with its attorneys regarding, and understands, this Agreement.

 

4

 

 

SECTION 6.     Governing Law; Submission to Jurisdiction; Waiver of Jury Trial. 

 

(a)     Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply.

 

(b)     Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Agreement or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit, action, proceeding or judgment. This Section 6 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions.

 

(c)     Waiver of Jury Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Agreement, the other Loan Documents or the transactions contemplated hereby or thereby.

 

SECTION 7.     No Actions, Claims, Etc. Each Obligor acknowledges and confirms that it has no knowledge of any actions, causes of action, claims, demands, damages or liabilities of whatever kind or nature, in law or in equity, against any Secured Party, in any case, arising from any action or failure of any Secured Party to act under any Loan Document on or prior to the date hereof, or of any offset right, counterclaim or defense of any kind against any of its respective obligations, indebtedness or liabilities to Secured Party under any Loan Document. Each Obligor unconditionally releases, waives and forever discharges (i) any and all liabilities, obligations, duties, promises or indebtedness of any kind of any Lender to such Obligor, except the obligations required to be performed by any Lender under the Loan Documents on or after the date hereof, and (ii) all claims, offsets, causes of action, suits or defenses of any kind whatsoever (if any), whether arising at law or in equity, whether known or unknown, which such Obligor might otherwise have against any Secured Party in connection with the Loan Documents or the transactions contemplated thereby, in the case of each of clauses (i) and (ii), on account of any past or presently existing condition, act, omission, event, contract, liability, obligation, indebtedness, claim, cause of action, defense, circumstance or matter of any kind. Each Obligor acknowledges that it may discover facts or law different from, or in addition to, the facts or law that it knows or believes to be true with respect to the claims released in this Section 7 and agrees, nonetheless, that this release shall be and remain effective in all respects notwithstanding such different or additional facts or the discovery of them. Each Obligor expressly acknowledges and agrees that all rights under Section 1542 of the California Civil Code are expressly waived. That section provides:

 

“A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.”

 

5

 

 

SECTION 8.     Miscellaneous.

 

(a)     No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents (including, without limitation, all such rights, privileges and remedies with respect to any Default, Event of Default or Material Adverse Effect, whether or not communicated to Lenders). Except as amended hereby, the Loan Agreement and other Loan Documents remain unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby.

 

(b)     Severability. In case any provision of or obligation under this Agreement shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

 

(c)     Headings. Headings and captions used in this Agreement (including the Exhibits, Schedules and Annexes hereto, if any) are included for convenience of reference only and shall not be given any substantive effect.

 

(d)     Integration. This Agreement constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof.

 

(e)     Counterparts. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. Executed counterparts delivered by facsimile or other electronic transmission (e.g., “PDF” or “TIF”) shall be effective as delivery of a manually executed counterpart.

 

(f)     Controlling Provisions. In the event of any inconsistencies between the provisions of this Agreement and the provisions of any other Loan Document, the provisions of this Agreement shall govern and prevail.

 

(g)     Loan Document. This Agreement is a Loan Document.

 

[Remainder of page intentionally left blank]

 

 

6

 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first above written.

 

 

	 	OBLIGORS:	 
	 	 	 
	
			 

				
			 

				
			 

			
	
			 

				AVINGER, INC.	
			 

			
	
			 

				
			 

				
			 

				
			 

			
	
			 

				
			By:

				
			/s/ Mark Weinswig

				
			 

			
	
			 

				
			Name:

				
			Mark Weinswig 

				
			 

			
	
			 

				
			Title:

				
			Chief Financial Officer

				
			 

			

 

 

[Signature Page to Amendment No. 5]

 

 

LENDERS:

 

Crg PARTNERS III L.P. 

	 	By Crg PARTNERS III GP L.P., its General Partner

	 	By Crg PARTNERS III GP LLC, its General Partner

 

	 	By	 /s/ Nathan Hukill	 
	 	 	Name: Nathan Hukill	 
	 	 	Title: Authorized Signatory	 

 

Crg PARTNERS III – PARALLEL FUND “a” L.P. 

	 	By Crg PARTNERS III – PARALLEL FUND “A” GP L.P., its General Partner

	 	By Crg PARTNERS III GP LLC, its General Partner

 

	 	By	 /s/ Nathan Hukill	 
	 	 	Name: Nathan Hukill	 
	 	 	Title: Authorized Signatory	 

 

Crg PARTNERS III – parallel fund “B” (cayman) L.P. 

	 	By Crg PARTNERS III (Cayman) GP L.P., its General Partner

	 	By Crg PARTNERS III GP LLC, its General Partner

 

	 	By	 /s/ Nathan Hukill	 
	 	 	Name: Nathan Hukill	 
	 	 	Title: Authorized Signatory	 
	 	 	 	 
	 	WITNESS: /s/ Nicole Nesson	 
	 	Name: Nicole Nesson	 

 

Crg PARTNERS III (cayman) LEV AIV L.P. 

	 	By Crg PARTNERS III (Cayman) GP L.P., its General Partner

	 	By Crg PARTNERS III GP LLC, its General Partner

 

	 	By	 /s/ Nathan Hukill	 
	 	 	Name: Nathan Hukill	 
	 	 	Title: Authorized Signatory	 
	 	 	 	 
	 	WITNESS: /s/ Nicole Nesson	 
	 	Name: Nicole Nesson	 

 

[Signature Page to Amendment No. 5]

 

 

CRG PARTNERS III (CAYMAN) UNLEV AIV I L.P. 

	 	By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner

	 	
			By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner

			

 

	 	By	 /s/ Nathan Hukill	 
	 	 	Name: Nathan Hukill	 
	 	 	Authorized Signatory	 
	 	 	 	 
	 	WITNESS: /s/ Nicole Nesson	 
	 	Name: Nicole Nesson	 

 

[Signature Page to Amendment No. 5]

Annex B to Compliance Certificate

 

 

Calculations of Financial Covenant Compliance

 

	
			I.

				
			Section 10.01: Minimum Liquidity

				 
	
			A.

				
			Amount of unencumbered (other than Liens securing the Obligations and Liens permitted pursuant to Section 9.02(c) and 9.02(j), provided that with respect to cash subject to a Permitted Priority Lien in connection with Permitted Priority Debt, there is no event of default under the documentation governing the Permitted Priority Debt) cash and Permitted Cash Equivalent Investments (which for greater certainty shall not include any undrawn credit lines), in each case, to the extent held in an account over which the Lenders (or the Control Agent on behalf of the Lenders) have (or has) a perfected security interest:

				
			$__________

			
	
			B.

				
			$3,500,000

				
			$3,500,000

			
	 	
			Is Line IA equal to or greater than Line IB?:

				
			Yes: In compliance; 

			No: Not in compliance

			
	
			II.

				
			Section 10.02(a)-(k): Minimum Revenue—Subsequent Periods

				 
	
			A.

				
			Revenues during the twelve month period beginning on January 1, 2015

				
			$__________

			
	 	
			[Is line II.A equal to or greater than $7,000,000?

				
			Yes: In compliance; 

			No: Not in compliance]1

			
	
			B.

				
			Revenues during the twelve month period beginning on January 1, 2016

				
			$__________

			
	 	
			[Is line II.B equal to or greater than $23,000,000?

				
			Yes: In compliance; 

			No: Not in compliance]2

			
	
			C.

				
			Revenues during the twelve month period beginning on January 1, 2017

				
			$__________

			
	 	
			[Is line II.C equal to or greater than $40,000,000?

				
			Yes: In compliance; 

			No: Not in compliance]3

			
	
			D.

				
			Revenues during the twelve month period beginning on January 1, 2018

				
			N/A

			

 

 

1 Include bracketed entry only on the Compliance Certificate to be delivered within 90 days of the end of 2015 pursuant to Section 8.01(b) of the Loan Agreement.

2 Include bracketed entry only on the Compliance Certificate to be delivered within 90 days of the end of 2016 pursuant to Section 8.01(b) of the Loan Agreement.

3 Include bracketed entry only on the Compliance Certificate to be delivered within 90 days of the end of 2017 pursuant to Section 8.01(b) of the Loan Agreement.

 

 

Annex B to Compliance Certificate

 

 

	
			E.

				
			Revenues during the twelve month period beginning on January 1, 2019

				
			N/A

			
	
			F.

				
			Revenues during the twelve month period beginning on January 1, 2020

				
			N/A

			
	
			G.

				
			Revenues during the twelve month period beginning on January 1, 2021

				
			$__________

			
	 	
			[Is line II.G equal to or greater than $8,000,000?

				
			Yes: In compliance; 

			No: Not in compliance]4

			
	
			H.

				
			Revenues during the twelve month period beginning on January 1, 2022

				
			$__________

			
	 	
			[Is line II.H equal to or greater than $10,000,000?

				
			Yes: In compliance; 

			No: Not in compliance]5

			
	
			I.

				
			Revenues during the twelve month period beginning on January 1, 2023

				
			$__________

			
	 	
			[Is line II.H equal to or greater than $12,000,000?

				
			Yes: In compliance; 

			No: Not in compliance]6

			
	
			J.

				
			Revenues during the twelve month period beginning on January 1, 2024

				
			$__________

			
	 	
			[Is line II.H equal to or greater than $14,500,000?

				
			Yes: In compliance; 

			No: Not in compliance]7

			
	
			K.

				
			Revenues during the twelve month period beginning on January 1, 2025

				
			$__________

			
	 	
			[Is line II.H equal to or greater than $17,000,000?

				
			Yes: In compliance; 

			No: Not in compliance]8

			

 

 

4 Include bracketed entry only on the Compliance Certificate to be delivered within 90 days of the end of 2021 pursuant to Section 8.01(b) of the Loan Agreement.

5 Include bracketed entry only on the Compliance Certificate to be delivered within 90 days of the end of 2022 pursuant to Section 8.01(b) of the Loan Agreement.

6 Include bracketed entry only on the Compliance Certificate to be delivered within 90 days of the end of 2023 pursuant to Section 8.01(b) of the Loan Agreement.

7 Include bracketed entry only on the Compliance Certificate to be delivered within 90 days of the end of 2024 pursuant to Section 8.01(b) of the Loan Agreement.

8 Include bracketed entry only on the Compliance Certificate to be delivered within 90 days of the end of 2025 pursuant to Section 8.01(b) of the Loan Agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]